Pronutria Biosciences, a Cambridge MA-based clinical stage biotechnology company developing a new class of therapeutics to mediate amino acid biology, completed a $39m Series C financing.
The round was led by new investor Fidelity Management & Research Company with participation from founding investor Flagship Ventures, among others.
The company will use the funds to advance its R&D programs.
Led by Robert Connelly, President and Chief Executive Officer, Pronutria develops a novel class of amino acid-based products for patients facing serious conditions who currently have few or no options. Research and development programs are conducted in several nutritional and therapeutic areas including muscle, metabolic, neurological and liver disorders.